|
GB202102610D0
|
|
Medical use
|
|
GB202100559D0
|
|
Medical use
|
|
GB202015771D0
|
|
Dosage regimen
|
|
WO2021058711A2
|
|
Antigen binding proteins
|
|
WO2021058709A1
|
|
Method of predicting production stability of clonal cell lines
|
|
GB202015188D0
|
|
Medical use
|
|
WO2021048291A1
|
|
Method for screening libraries
|
|
GB202014116D0
|
|
Dosage regimen
|
|
WO2021046293A1
|
|
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
|
|
WO2021043961A1
|
|
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
GB202012477D0
|
|
Medical Use
|
|
WO2021024133A2
|
|
Biopharmacuetical compositions and related methods
|
|
WO2021023609A1
|
|
Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor
|
|
WO2021018941A1
|
|
Methods of treating cancer
|
|
WO2021009050A1
|
|
Reducing malaria transmission
|
|
WO2021004910A1
|
|
Combination for the treatment of infections caused by mycoplasma genitalium
|
|
WO2020261114A1
|
|
2,3-dihydroquinazolin compounds as nav1.8 inhibitors
|
|
WO2020261097A1
|
|
Il1rap binding proteins
|
|
WO2020254369A1
|
|
Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of fimh
|
|
US2020299309A1
|
|
Compounds useful in HIV therapy
|
